Related Experiment Video
Updated: May 17, 2026
09:06
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
Interference of the CD30-CD30L pathway reduces atherosclerosis development.
Amanda C Foks1, Ilze Bot, Vanessa Frodermann
1Division of Biopharmaceutics, Leiden Amsterdam Center for Drug Research, Leiden University, Leiden, The Netherlands. a.c.foks@lacdr.leidenuniv.nl
Arteriosclerosis, Thrombosis, and Vascular Biology
|October 23, 2012
Summary
Blocking the CD30-CD30L pathway significantly reduced atherosclerosis development in mice. This intervention modulated T-cell function, highlighting a novel therapeutic target for cardiovascular disease.
Area of Science:
- Immunology and Cardiovascular Science
Background:
- Costimulatory molecules regulate T-cell activation and immune responses.
- The CD30-CD30L pathway, part of the TNF receptor superfamily, influences T and B cell activity.
- This pathway is implicated in atherosclerosis initiation and progression.
Purpose of the Study:
- To investigate the role of the CD30-CD30L pathway in atherosclerosis development.
- To determine if targeting CD30-CD30L impacts atherosclerotic lesion formation.
Main Methods:
- Low-density lipoprotein receptor-deficient mice were fed a Western-type diet.
- Mice received an anti-CD30L antibody treatment for 8 weeks.
- Atherosclerotic lesion formation, T-cell populations, and splenocyte proliferation were analyzed.
Main Results:
- Anti-CD30L treatment reduced atherosclerotic lesion formation in the aortic root by 35%.
- A decrease in adventitial CD3(+) T cells was observed, with no changes in collagen or macrophage content.
- Splenocyte proliferation decreased by 53%, accompanied by reduced T-cell numbers, indicating CD30-CD30L primarily affects T-cell responses.
Conclusions:
- Interruption of the CD30-CD30L pathway effectively reduces early atherosclerosis development.
- The CD30-CD30L pathway modulates T-cell function, representing a novel therapeutic target.
- This study is the first to demonstrate the role of CD30-CD30L in atherosclerosis modulation via T-cell function.
Related Concept Videos
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:38Inflammation
Overview
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...